This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
The Board of Red Emperor Resources NL (“Red Emperor” or the “Company”) is pleased to provide the following announcement with respect to an exciting new farm-in acquisition and upcoming drill program.
OISHF REMPF OEL RMP OTTEF OISHY RMP 88E OSH
88 Energy Limited (ASX: 88E) (“88 Energy” or the “Company”) is pleased to announce the following update in relation to an expansion of its projects located on the North Slope of Alaska.
OEL OTTEF 88E
Proactive's oil and gas correspondent Jamie Ashcroft discusses the restarting this week of 88 Energy Ltd's (LON:88E, ASX:88E) Icewine-2 well testing programme.
88 Energy Ltd (LON:88E, ASX:88E) confirmed that the Icewine-2 well testing programme resumed as scheduled on June 11, at 22:30, and the well is now continuing to flow back fluids.
Anticipation is rising for investors in 88 Energy Ltd (LON:88E, ASX:88E) now that a date has been set for the restart of the Icewine-2 well programme in Alaska.
88 Energy Ltd (LON:88E, ASX:88E) shares gained on Monday after the firm said it can now start a proper countdown to testing for the Icewine-2 shale well in Alaska.I
88 Energy Ltd (LON:88E, ASX:88E) can now start a proper countdown to testing for the Icewine-2 shale well in Alaska.
Dave Wall, managing director of 88 Energy Limited (LON:88E, ASX:88E), caught up with Proactive Investors to discuss their recent A$17mln fundraise which will be used predominantly to fund the ongoing evaluation of conventional and unconventional oil targets on Alaska’s North Slope.
Anglo-Aussie junior 88 Energy Limited (LON:88E, ASX:88E) has unveiled plans to raise up to A$17mln that will be used to fund the ongoing evaluation of conventional and unconventional oil targets on Alaska’s North Slope.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to ASX:88E / 88 ENERGY LIMITED on message board site Silicon Investor.
|88 Energy (LSE:88E) potential to deliver a high level of pro|